Author: sf-admin

SHANGHAI, CHINA, June 23, 2026 (GLOBE NEWSWIRE) — YunTuo Single Malt Whisky Distillery, Diageo’s first whisky distillery in China, has recently gained international recognition across the whisky industry, global media and architecture, marked by three wins at the 2026 Icons of Whisky China Awards, feature coverage in The Economist, and architectural recognition from ArchDaily. As more whisky distilleries enter the view of the global industry and markets, YunTuo Single Malt Whisky Distillery has emerged as a leading distillery in Chinese Whisky industry. With recognition spanning the spirits industry, international media and architecture, YunTuo is helping define a distinctive path for Chinese-origin single malt whisky.

¹ Lower of the two daily volume-weighted average prices over the period immediately preceding each issue.
² At least equal to the volume-weighted average of the share prices over the three trading sessions immediately preceding the setting of the issue price, subject to a discount of up to 30%.
³ The number of shares that may be issued under the agreement will be specified in the monthly information on the number of shares and voting rights posted on the Company’s website.
⁴ Delegation of competence to the Board of Directors to increase the share capital for the benefit of a category of investors (physical or moral persons, trusts, investment funds or other financial placement vehicles; strategic partners of the Company; or all other creditors) without preferential right of subscription of the shareholders.
⁵ On the basis of the 93,762,506 shares comprising the share capital, as of 31 May 2026.
⁶ On a fully diluted basis, including 30,372,852 shares that may be issued upon exercise of all the outstanding dilutive instruments as of 31 May 2026.

1 Plus petit des deux cours moyens quotidiens pondérés par les volumes sur la période précédant immédiatement chaque émission.
2 Au moins égal à la moyenne pondérée par les volumes des cours des trois dernières séances de bourse précédant la fixation du prix de l’émission, éventuellement diminuée d’une décote maximale de 30%.
3 Le nombre d’actions susceptibles d’être émises en vertu de cet accord sera précisé dans l’information mensuelle relative au nombre d’actions et de droits de vote publiée sur le site Internet de la Société.
4 Délégation de compétence consentie au Conseil d’Administration pour augmenter le capital au bénéfice d’une catégorie de bénéficiaires, (Personne(s) physiques ou morales, trust, fonds d’investissement ou autres véhicules de placement ; partenaire(s) stratégique(s) de la Société ; ou toute personne détenant une créance certaine, liquide et exigible sur la Société) avec suppression du droit préférentiel de souscription des actionnaires à leur profit.
5 Sur la base des 93 762 506 actions composant le capital social au 31 mai 2026.
6 Sur une base diluée incluant 30 372 852 actions susceptibles d’être émises en cas d’exercice de l’ensemble des instruments dilutifs existants au 31 mai 2026.

Press Release

Akkodis Studie: Vertrauen in KI‑Skalierung sinkt, obwohl Investitionen steigen. Herausforderung: Integration statt Technologie, Fokus verschiebt sich zu In

Akkodis study: confidence in AI scaling declines despite rising investment. Challenge shifts to integration, with focus moving from efficiency to innovatio

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company’s share capital (the “Share Capital Amendment”).

Vancouver, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company“) is pleased to provide an update respecting its previously announced (see the Company’s news release dated May 29, 2026) non-brokered private placement (the “Offering”) under which it will raise aggregate gross proceeds of up to $500,000 through the issuance of up to 4,166,667 units (each, a “Unit”) at a price of $0.12 per Unit. Each Unit will consist of one Class A common share (each, a “Share”) and one Share purchase warrant (each, a “Warrant”, entitling the holder to purchase one Share at a price of $0.18 for five years from the date of issuance). 

The data-center build-out is being financed with record borrowing, much of it private. A former Treasury and Pentagon advisor traces where that risk ultimately lands.

The data-center build-out is being financed with record borrowing, much of it private. A former Treasury and Pentagon advisor traces where that risk ultimately lands.

Pricing of CNH Industrial Capital LLC $600 million notes

New York, NY, June 22, 2026 (GLOBE NEWSWIRE) — Wilco 63 Corporation (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on June 18, 2026 on The Nasdaq Global Stock Market LLC (“Nasdaq”) under the ticker symbol “WLCOU.” Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “WLCO” and “WLCOW,” respectively. Of the proceeds received from the consummation of the initial public offering (including the exercise of the over-allotment option) and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in trust.

2026 haul is most in statewide public TV network’s history

2026 haul is most in statewide public TV network’s history

Southfield, MI, June 22, 2026 (GLOBE NEWSWIRE) — Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust (“REIT”) that owns and operates, or has an interest in, manufactured housing (“MH”) and recreational vehicle (“RV”) communities (collectively, the “properties”), today announced the appointment of Ileana McAlary as General Counsel, Executive Vice President, and Secretary, effective June 29, 2026.

NEW YORK, NY, June 22, 2026 (GLOBE NEWSWIRE) — Texas Ventures Acquisition IV Corp (the “Company”) announced today the closing of its initial public offering of 17,250,000 units, which includes 2,250,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $172,500,000.

LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET.

DALLAS, June 22, 2026 (GLOBE NEWSWIRE) — Ridgepost Capital, Inc. (NYSE: RPC) (“Ridgepost” or “Ridgepost Capital”) today announced it has completed its previously announced acquisition of Stellus Capital Management, LLC (“Stellus”), a leading U.S. direct lender focused on the lower-middle market with approximately $4 billion in assets under management. Stellus will continue to be managed by its current partners who will lead day-to-day operations, including investment decisions and investment committee processes.

BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).